Beilei Cai
YOU?
Author Swipe
View article: Drought-Induced Epigenetic Memory in the cambium of Poplar Trees persists and primes future stress responses
Drought-Induced Epigenetic Memory in the cambium of Poplar Trees persists and primes future stress responses Open
Understanding how perennial plants such as trees perceive, integrate and memorize environmental stresses like water deficit is crucial in the context of climate change. We investigated short-term and transannual memory of water deficit in …
View article: Second line advanced or metastatic non-small cell lung cancer treatment after chemo-immunotherapy: a retrospective study
Second line advanced or metastatic non-small cell lung cancer treatment after chemo-immunotherapy: a retrospective study Open
rwPFS and OS were consistent with clinical trials of 2L IO regimens. The few patients who received IO in 1L and 2L had favorable rwPFS and OS. Future research on sequential IO therapies in 1L and 2L aNSCLC is warranted.
View article: Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study
Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study Open
Aim: To assess real-world clinical outcomes with standard therapies for advanced non-small-cell lung cancer (aNSCLC) with METexon14 skipping mutation (METex14).Methods: In an oncologists-led retrospective review of medical records, data we…
View article: Computational repurposing and preclinical validation of colquhounia root tablets for membranous nephropathy
Computational repurposing and preclinical validation of colquhounia root tablets for membranous nephropathy Open
Current therapeutics of membranous nephropathy (MN) hold dilemmas of limited clinical response rates, high recurrence rate, and unavoidable adverse effects.1 Colquhounia Root Tablet (CRT) is a Chinese patent medicine prepared from the peel…
View article: Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib Open
Aim: To assess real-world clinical outcomes in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practic…
View article: Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US
Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US Open
Background MET exon 14 skipping mutation ( MET ex14) is observed in ~3% of non-small cell lung cancer (NSCLC) cases and has been shown to be an independent poor prognostic factor associated with shorter overall disease-specific survival. B…
View article: Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer
Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer Open
Although the 1L treatment paradigm has recently shifted to IO-based regimens, 41.5% did not survive past 1L. Median 1L PFS did not exceed 1.5 years and median OS remained limited across all 1L treatment groups, illustrating continued unmet…
View article: 562 Real-world assessment of current treatment patterns and clinical outcomes among patients with EGFR and ALK wild type non-small cell lung cancer (NSCLC) in the US
562 Real-world assessment of current treatment patterns and clinical outcomes among patients with EGFR and ALK wild type non-small cell lung cancer (NSCLC) in the US Open
Background Treatment for advanced non-small cell lung cancer (NSCLC) has dramatically advanced in the past 5 years with the advent of immunotherapy (IO). This study sought to describe treatment patterns and clinical outcomes in a represent…
View article: Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non‐small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real‐world retrospective observational study
Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non‐small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real‐world retrospective observational study Open
Aims Adjuvant chemotherapy has been shown to improve survival in patients with completely resected early‐stage non‐small cell lung cancer (NSCLC). This study evaluated real‐world relapse rates and healthcare resource utilization in patient…
View article: Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a <i>MET</i> exon 14 skipping mutation in the United States
Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a <i>MET</i> exon 14 skipping mutation in the United States Open
The estimated budget impact of including capmatinib for mNSCLC with a METex14 skipping mutation is minimal, and the increased drug costs were partially offset by savings in AEs, and progression-related and terminal care costs.
View article: Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag
Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag Open
Purpose: This study evaluated healthcare resource utilization (HCRU), and direct costs among severe aplastic anemia (SAA) patients treated with eltrombopag (EPAG) using US claims data.Methods: This retrospective, real-world claims database…
View article: <p>Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States</p>
Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States Open
High response rates combined with reduced rescue medication use and mortality in patients treated with eltrombopag and IST mediated higher medication costs.
View article: Healthcare costs and resource utilization in patients with severe aplastic anemia in the US
Healthcare costs and resource utilization in patients with severe aplastic anemia in the US Open
Purpose: This study aimed to evaluate the healthcare resource utilization (HCRU) and costs for patients with severe aplastic anemia (SAA) using US claims data. Methods: This retrospective, observational database study analyzed claims data …
View article: Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study
Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study Open
Background Using data from four tertiary referral centers in the U.S., we assessed real-world treatment patterns and clinical outcomes of patients with advanced lung neuroendocrine tumors (NETs). Subjects, Materials, and Methods We perform…
View article: Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study
Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study Open
Background We assessed treatment patterns and outcomes of patients with advanced gastrointestinal (GI) neuroendocrine tumors (NET) at four large tertiary referral centers in the U.S. Patients and Methods We performed a retrospective chart …
View article: Healthcare costs and resource utilization in patients with severe aplastic anemia in the US
Healthcare costs and resource utilization in patients with severe aplastic anemia in the US Open
Purpose: This study aimed to evaluate the healthcare resource utilization (HCRU) and costs for patients with severe aplastic anemia (SAA) using US claims data. Methods: This retrospective, observational database study analyzed claims data …
View article: Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag
Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag Open
Purpose: This study evaluated healthcare resource utilization (HCRU), and direct costs among severe aplastic anemia (SAA) patients treated with eltrombopag (EPAG) using US claims data. Methods: This retrospective, real-world claims databas…
View article: Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome
Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome Open
To evaluate association of carcinoid syndrome (CS) symptom burden and somatostatin analog (SSA) duration with quality of life (QoL) using Functional Assessment of Cancer Therapy-General (FACT-G) and Patient-Reported Outcomes Measurement In…
View article: Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors
Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors Open
Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors
View article: First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA
First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA Open
This study reports utilization and costs associated with different treatment therapies. Costs were higher in year 1 than year 2. This two-database study offers new information on the magnitude and trends in the cost of pharmacologically-tr…
View article: Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors
Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors Open
GI NET patients with CS were 2-4 times as likely to have preexisting diagnoses (i.e., liver disorder, enlarged lymph nodes, abdominal mass) than non-CS patients.
View article: Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis
Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis Open
In this study, 60% of patients initiated treatment with SSA alone or in combination. The relatively long time to discontinuation suggests possible sustained effectiveness and tolerability.
View article: Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy
Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy Open
Funding for the research study and resultant publication was provided by Boehringer Ingelheim. Shetty is an employee of Boehringer Ingelheim. Cai was an employee of Boehringer Ingelheim at the time of the study. Raju and D'Souza are employ…